REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

This study tests REGN7508, a new drug being investigated to prevent dangerous blood clots (venous thromboembolism or VTE) in adults with advanced solid tumor cancers, who are at higher risk for clotting due to their cancer or its treatment. **You may be eligible if...** - You are an adult with a confirmed advanced or metastatic solid tumor cancer - You have a moderate-to-high clotting risk score (Khorana score of 2 or above) OR a genetic mutation in your tumor known to raise clotting risk - Your overall health is acceptable (ECOG 0-2) **You may NOT be eligible if...** - You have a known bleeding disorder (such as hemophilia or von Willebrand disease) or a high bleeding risk - Your cancer is only a skin cancer (basal cell or squamous cell) - You have a brain tumor or brain metastases - You have a history of blood clots (VTE or ATE) that required anticoagulation - You have any condition that could confound the results or put you at greater risk Talk to your doctor to see if this trial is right for you.